NCT03810144View on ClinicalTrials.gov

Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test

CompletedOBSERVATIONAL
Enrollment

444

Participants

Timeline

Start Date

October 22, 2018

Primary Completion Date

August 16, 2022

Study Completion Date

October 16, 2022

Conditions
Rheumatoid Arthritis
Interventions
GENETIC

Vectra MBDA Test

Vectra Guided versus Usual Care

Trial Locations (11)

20639

MedStar Shah Medical Group, Hollywood

20770

Arthritis & Pain Associates of PG County, Greenbelt

20902

The Center for Rheumatology and Bone Research, Wheaton

21046

Arthritis Care Specialists of Maryland, Columbia

21060

Mid-Atlantic Rheumatology, Glen Burnie

21215

Lifebridge Sinai Hospital of Baltimore, Baltimore

21228

Nasseri Clinic of Arthritis & Rheumatic Diseases, LLC., Catonsville

21286

Rheumatology Associates of Baltimore LLC, Baltimore

21401

Annapolis Rheumatology LLC, Annapolis

21502

Klein & Associates, Cumberland

Klein & Associates, Hagerstown

All Listed Sponsors
collaborator

Laboratory Corporation of America

INDUSTRY

lead

Sequenom, Inc.

INDUSTRY

NCT03810144 - Impact of Guided Care With the Vectra Multi-biomarker Disease Activity (MBDA) Blood Test | Biotech Hunter | Biotech Hunter